Restoring Ears. Restoring Childhoods.
Earicular is a tissue-engineered reconstruction project to restore natural ear shape for patients with congenital deformities.
Learn MoreEaricular combines clinical insight, allograft tissue, and 3D bioprinting to address microtia in a way that's gentler on patients.
Microtia is a congenital condition in which the outer ear is underdeveloped or absent due to abnormal fetal ear formation.
Reconstructive surgery is typically delayed until later childhood or early adolescence, when rib cartilage is fully developed and large enough to harvest.
Cartilage allografts are increasingly used in reconstructive surgery with strong clinical outcomes.
Extearna® is a minimally processed costal cartilage allograft sourced from pediatric and young adult donors, a promising material for auricular reconstruction.
Visit MTF Biologics →Earicular's goal is to develop 3D bioprinted auricular constructs using Extearna® that match the biomechanical, biochemical, and clinical performance of autologous costal cartilage.
The result: fewer surgeries, reduced operative time, and a smoother experience for pediatric patients.
Costal cartilage allografts from young donors retain native ECM cues that support remodeling and integration. Pairing Extearna® with bioprinting lets us deliver patient-specific ear geometry without the morbidity of harvesting a child's own rib.
By eliminating the wait for a child's rib to mature, we can shift reconstruction toward the years when it matters most: before peers, photographs, and self-image.
Four pillars of research drive Earicular's approach to a softer, earlier reconstruction.
A photocrosslinkable hydrogel that's biocompatible and mechanically tunable, with support for cell adhesion. Derived from collagen-based gelatin, GelMA breaks down into harmless amino acids as native tissue takes over.
We incorporate decellularized costal cartilage ECM particles into the GelMA matrix. This composite bioink carries the biochemical cues of native cartilage, then gets bioprinted into auricular constructs.
Conventional autologous reconstruction requires harvesting rib cartilage. Surgeons must wait until ages 6-10 for full rib development, leaving children to grow up without an ear during the most socially formative years.
With our bioprinted construct, surgery can happen before full cartilage development. We size constructs to a near-adult shape using established growth proportions, then implant them early.
As the child grows, GelMA disintegrates and leaves behind cartilage similar to an autologous implant; surgeons no longer need to suture an ear pre-operation.
Hover any row to highlight it, or hover a column header to compare across all rows.
| Feature | MEDPOR Synthetic Graft | Autologous Costal Cartilage | Extearna® |
|---|---|---|---|
| Low risk of complications (infection, extrusion, rejection, fracture) | -- Risks foreign body response | -- Can lead to chest wall deformities | ++ No foreign body response |
| Low risk of chest wall deformity | ++ No rib harvest | -- Requires rib harvest from patient | ++ No rib harvest |
| Minimal pain and scarring | + No separate donor site | -- Muscle and cartilage operation | + No separate donor site |
| Less surgically demanding | + Requires TPF flap | -- Requires two separate procedures | + Requires TPF and framework |
| Short recovery time | + Local healing | -- Long monitoring period | + Local healing |
| Reconstruction can be performed at an earlier age | ++ No donor needed | -- Sufficient cartilage at age 9-10 | ++ Can implant as early as three years |
The global cartilage repair market is expanding rapidly, with allograft-based solutions at the forefront of that growth.
| Market Size (Current) | Market Size (Future) | Market Trends | Market Growth Rate | Key Success Factors | Main Competitors | Main Competitor Key Patents |
|---|---|---|---|---|---|---|
|
$5.98 billion
The global cartilage repair market was estimated at USD 5.98 billion in 2024. North American cartilage repair held the largest revenue share at 51.5% of the industry. Demand primarily from reconstructive and ENT surgeries. |
$7.65 billion
(5-year projection) The global cartilage repair market is expected to grow at a CAGR of 5.1% from 2025 to 2030. The market report shows both cell and non-cell based treatment modalities [5]. |
Cell-based modalities segment held the largest market share of 60.5% in 2024 and is expected to grow at the fastest rate. Intrinsic repair stimulus segment held the largest market revenue share [5]. Predicting shift in allograft use due to shorter operating times and increased performance. |
5.1% CAGR
(5-year projection, 2025-2030) |
|
~20.7% ~27.1% Stryker's MEDPOR® offers synthetic (porous polyethylene) ear implants for reconstructive surgery. Available disclosures focus on broader segments; product-category level not disclosed. |
U.S. Patent No. 7655047 Polyethylene matrix and titanium mesh design for fibrovascular ingrowth. Assigned to Porex Surgical, Inc., acquired by Stryker. Referenced in product literature for MEDPOR TITAN [6]. |
| Stakeholder | Current Commitment | Desired Commitment | Change Impact | Description of Change & Impact | Resistance Level | Positive Factors | Resistance Factors | Tactics & Actions |
|---|---|---|---|---|---|---|---|---|
| Plastic surgeons / ENT surgeons | Medium | High | High | Surgical procedures will adapt to product; must adjust to material, composition, and structure to reduce patient morbidity | Medium | Lower patient readmission, morbidity (study [3] shows nearly no site morbidity with younger donors), long-term outcomes | Graft integration surgical procedures, availability of product (cartilage from cadavers), can be harder to use than synthetics; study [1] claims higher aesthetic outcomes with PPE implants | Provide clinical trial data, conduct demos |
| Hospital administrators | Medium | High | Medium | Reduction in surgery time, cost, and inventory management; fewer donor site complications; reduced cost of care | Medium | Lower patient readmissions; study [4] shows considerably less complication rates when compared to traditional IIHC grafts | Budget approval cycles, high costs of allograft | Cost and budget analyses, data showing success |
| Patients | Medium | High | Medium | Access to a less invasive reconstructive auricular graft with better integration. "Despite the higher costs, FFRG can provide a sufficient amount of tissue for grafting avoiding donor site complications and reducing the operative time" [1] | Low | Less invasive surgery, faster recovery times, better tissue integration, no autologous grafting, better aesthetic outcome | Cost, lack of cadaver donor, less visibility. [2] claims that cost may be higher for FFRG grafts than autologous or IIHC | Advertising, marketing, educational brochures, outreach with safety and regulatory compliance |
| Advisors, Mentors | Medium | High | High | Provides guidance and approves key decisions; must be updated regularly | Low | Interested in student success and seeing tangible outcomes | Time limited; communication restricted due to busy schedules | Weekly check-ins, progress reports, involvement in critical decisions, defined meetings |
A UC Irvine BME senior design team blending research, clinical insight, and engineering execution.
Team Lead, Research & Testing
B.S. BME
liliand2@uci.eduResearch & Testing
B.S. BME
houstotn@uci.eduClinical Research
B.S. BME
sabanuma@uci.eduMarket Research & Communication
B.S. BME
jbrinsko@uci.eduClinical Research
B.S. BME
sfaccio@uci.eduData Analyst
B.S. BME & B.S. CS
jovann@uci.eduInterested in Earicular's research or want to collaborate? Reach out to the team.
✉ liliand2@uci.edu